Arcutis Biotherapeutics (ARQT) announced that the Journal of American Medical Association Dermatology published the results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE ...

Results showed that ZORYVE foam, used as a once-daily monotherapy, not only improved psoriasis symptoms but also provided rapid relief from itch, with noticeable effects within 24 hours of the ...

ZORYVE foam 0.3% shows significant efficacy for scalp and body psoriasis, with FDA review anticipated by May 2025. Arcutis Biotherapeutics, Inc. announced positive results from a pivotal Phase 3 ...

At Week 8, 70.9% of those treated with ZORYVE foam versus 31.3% treated with vehicle achieved at least 75% improvement in Psoriasis Scalp Severity Index (PSSI-75) (P<.001), another secondary endpoint.

Results showed that ZORYVE foam, used as a once-daily monotherapy, not only improved psoriasis symptoms but also provided rapid relief from itch, with noticeable effects within 24 hours of the first ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Discover Arcutis Biotherapeutics' Q1 2025 earnings highlights: ZORYVE's growth, upcoming product launches, and a confident path to cash breakeven by 2026.

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy66.4% of individuals treated with ZORYVE foam achieved Scalp-I ...

Q1 2025 net product revenue for ZORYVE ® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible ...